Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23388427 | 1.00 | ADORA2A (0.61) | ADORA2AADORA1ADORA3ADORA2BKCNJ1 | |
| SCHEMBL29616988 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29944508 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388289 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29616971 | 0.88 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388364 | 0.88 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL23388316 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1HSP90AA1TRAP1 | |
| SCHEMBL23388311 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29616977 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1HSP90AA1TRAP1 | |
| SCHEMBL29616990 | 0.87 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425756-B | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-114829363-B | Adenosine receptor antagonist compounds | 日东制药株式会社 | 2024-10-01 | — | — | CN | disclosed |
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| EP-4061817-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.